Verona Pharma plc (VRNA) Financial Statements (2025 and earlier)

Company Profile

Business Address 3 MORE LONDON RIVERSIDE
LONDON, SE1 2RE
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments271,772227,827148,380187,986
Cash and cash equivalents271,772227,827148,380187,986
Receivables   58
Inventory, net of allowances, customer advances and progress billings    
Inventory    
Prepaid expense3,6172,4994,0374,538
Other current assets3,3653,3882,0631,720
Other undisclosed current assets10,9549,28215,5838,202
Total current assets:289,708242,996170,063202,504
Noncurrent Assets
Operating lease, right-of-use asset2,8478548991,050
Property, plant and equipment247380107
Intangible assets, net (including goodwill)545545545545
Goodwill545545545545
Contract with customer, asset, after allowance for credit loss15,00015,00015,000 
Total noncurrent assets:18,41616,47216,5241,702
TOTAL ASSETS:308,124259,468186,587204,206
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,07716,66232,44711,041
Taxes payable147 
Accounts payable3,4922,91010,044178
Accrued liabilities3,58513,75222,25610,863
Deferred revenue    
Other liabilities4351,409327118
Other undisclosed current liabilities1,1809586483,044
Total current liabilities:8,69219,02933,42214,203
Noncurrent Liabilities
Long-term debt and lease obligation48,3749,7685,1605,149
Long-term debt, excluding current maturities48,3749,7684,8744,635
Liabilities, other than long-term debt1,775205  
Operating lease, liability1,775205286514
Other undisclosed noncurrent liabilities  (286)(514)
Total noncurrent liabilities:50,1499,9735,1605,149
Total liabilities:58,84129,00238,58219,352
Equity
Equity, attributable to parent249,283230,466148,005184,854
Common stock42,77140,52631,85531,794
Treasury stock, value(1,517)(1,549)(603)(1,700)
Additional paid in capital601,063529,187385,070366,411
Accumulated other comprehensive loss(4,601)(4,601)(4,601)(4,601)
Accumulated deficit(388,433)(333,097)(263,716)(207,050)
Total equity:249,283230,466148,005184,854
TOTAL LIABILITIES AND EQUITY:308,124259,468186,587204,206

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues 45840,000 
Cost of revenue  (346)  
Gross profit: 11240,000 
Operating expenses(67,569)(75,862)(113,313)(74,277)
Operating loss:(67,569)(75,750)(73,313)(74,277)
Nonoperating income13,6747,30217,7269,277
Investment income, nonoperating12,7612,82114121
Gain (loss), foreign currency transaction, before tax1,866(3,817)1762,060
Interest and debt expense(2,057)(815)(340)(35)
Loss from continuing operations before equity method investments, income taxes:(55,952)(69,263)(55,927)(65,035)
Other undisclosed income from continuing operations before income taxes2,05781534035
Loss from continuing operations before income taxes:(53,895)(68,448)(55,587)(65,000)
Income tax expense (benefit)(474)(253)18(146)
Loss from continuing operations:(54,369)(68,701)(55,569)(65,146)
Loss before gain (loss) on sale of properties:(55,569)(65,146)
Net loss available to common stockholders, diluted:(54,369)(68,701)(55,569)(65,146)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(54,369)(68,701)(55,569)(65,146)
Comprehensive loss:(54,369)(68,701)(55,569)(65,146)
Other undisclosed comprehensive loss, net of tax, attributable to parent    (2,321)
Comprehensive loss, net of tax, attributable to parent:(54,369)(68,701)(55,569)(67,467)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: